Fennec (FENC) Pharmaceuticals announced that Norgine Pharmaceuticals, a European specialist pharmaceutical company, has received positive final draft guidance from National Institute for Health and Care Excellence recommending Pedmarqsi for the prevention of cisplatin-induced hearing loss in patients (aged 1 month to 17 years) with localized, non-metastatic, solid tumors. Pedmarqsi is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity, or hearing loss, induced by cisplatin chemotherapy in patients 1 month to less than18 years of age with localized, non-metastatic solid tumors. In March, Fennec entered into an exclusive licensing agreement under which Norgine will commercialize Pedmarqsi in Europe, Australia, and New Zealand.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FENC: